Skip to main content
Terug
PVLA logo

Palvella Therapeutics, Inc.

Datakwaliteit: 100%
PVLA
NASDAQ Healthcare Biotechnology
€ 117,04
▲ € 4,54 (4,04%)
Marktkapitalisatie: 1,39B
Dagbereik
€ 109,97 € 118,88
52-Weeksbereik
€ 18,23 € 151,18
Volume
246.172
50D / 200D Gem.
€ 103,28 / € 71,39
Vorige Slotkoers
€ 112,50

Koershistorie

Financiële Trends

Sectorvergelijking

vs Healthcare sector mediaan (626 peers)

Metriek Aandeel Sector Mediaan
P/E -79,5 0,4
P/B 22,1 2,9
ROE % -59,4 3,8
Net Margin % 3,9
Rev Growth 5Y % 10,0
D/E 0,0 0,2

Koersdoel Analisten

Hold
€ 203,92 +74.2%
Low: € 143,00 High: € 255,00
Forward WPA
-€ 3,88
Omzet Sch.
27000

Winstschattingen

Periode WPA Sch. Omzet Sch. Analisten
FY2029 € 7,28
€ 7,28 – € 7,28
310 M 4
FY2028 -€ 0,74
-€ 7,04 – € 11,06
130 M 10
FY2027 -€ 4,99
-€ 9,33 – -€ 2,66
25 M 11

Belangrijkste Punten

Earnings declined -193,27% over the past year
Debt/Equity of 0,00 — conservative balance sheet
Negative free cash flow of -10,84M
PEG of 0,01 suggests growth is underpriced

Groei

Revenue Growth (5Y)
N/A
Revenue (1Y)N/A
Earnings (1Y)-193,27%
FCF Growth (3Y)N/A

Kwaliteit

Return on Equity
-59,37%
ROIC-16,89%
Net MarginN/A
Op. MarginN/A

Veiligheid

Debt / Equity
0,00
Current Ratio7,33
Interest Coverage-3,27

Waardering

P/E Ratio
-79,47
P/B Ratio22,13
EV/EBITDAN/A
Dividend Yield0,00%

All Fundamental Metrics

Growth
Revenue Growth (1Y) N/A Revenue Growth (3Y) N/A
Earnings Growth (1Y) -193,27% Earnings Growth (3Y) N/A
Revenue Growth (5Y) N/A Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 0,0 Net Income (TTM) -17,43M
ROE -59,37% ROA -19,76%
Gross Margin N/A Operating Margin N/A
Net Margin N/A Free Cash Flow (TTM) -10,84M
ROIC -16,89% FCF Growth (3Y) N/A
Safety
Debt / Equity 0,00 Current Ratio 7,33
Interest Coverage -3,27 Dividend Yield 0,00%
Valuation
P/E Ratio -79,47 P/B Ratio 22,13
P/S Ratio N/A PEG Ratio 0,01
EV/EBITDA N/A Dividend Yield 0,00%
Market Cap 1,39B Enterprise Value 1,30B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2024 FY2023 FY2022 FY2021
Revenue 0,0 0,0 25,90M 31,42M
Net Income -17,43M 18,69M -33,28M -45,74M
EPS (Diluted) -7,83 14,74 -29,61 -56,69
Gross Profit 0,0 0,0 23,12M 29,05M
Operating Income -14,10M -11,87M -43,47M -51,83M

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2024 FY2023 FY2022 FY2021 FY2020
Total Assets 88,23M 7,55M 16,52M 153,56M 105,01M
Total Liabilities 25,63M 11,43M 39,70M 102,81M 73,98M
Shareholders' Equity 62,61M -3,88M -23,17M 50,76M 31,03M
Total Debt 0,0 0,0 0,0 14,89M 16,96M
Cash & Equivalents 83,60M 7,35M 16,05M 117,76M 70,44M
Current Assets 88,23M 7,55M 16,52M 127,63M 75,72M
Current Liabilities 12,04M 2,36M 5,78M 50,56M 22,15M